SimBioSys 获 FDA 许可的 TumorSight Risk 可预测乳腺癌复发风险
SimBioSys 用 NVIDIA 技术做了个 FDA 许可的工具，术前就能估算乳腺癌 5 年和 10 年复发风险，对患者太有用了。
SimBioSys 推出的 TumorSight Risk 已获 FDA 许可，基于 NVIDIA 技术运行。该工具将现有乳腺 MRI 影像与病理和临床信息结合，估算癌症在 5 年和 10 年内的复发风险。针对 HR 阳性、HER2 阴性的早期乳腺癌患者，相关洞察可在手术前生成，帮助患者和医生在讨论治疗方案时掌握更多信息。
After a breast cancer diagnosis, one of the hardest questions is whether it will come back.
@SimBioSys is helping doctors and patients better understand that risk. Powered by NVIDIA technology, its FDA-cleared TumorSight Risk analyzes an existing breast MRI alongside pathology and clinical information to estimate the risk of cancer returning at five and ten years.
For women with HR-positive, HER2-negative early-stage breast cancer, those insights can be available before surgery, giving them and their doctors more information as they talk through treatment options.
AI can help give patients and their doctors more information when the decisions ahead feel most difficult.
